Generic Series: An Introduction to the Canadian Generics Market - Key trends and leading companies shaping the market

Table of Contents

• CHAPTER 1 EXECUTIVE SUMMARY
  • Scope of the report
  • Key findings
• CHAPTER 2 OVERVIEW OF THE CANADIAN GENERICS MARKET
  • Scope
  • Introduction to the Canadian pharmaceutical market
    • Canada' s pharmaceutical market has experienced double-digit prescription sales growth since 2002
    • The generics market represents a significant proportion of both prescription volume and total market value
  • Key issues affecting the Canadian generics market
    • The establishment of the Canadian generics market
    • Differences in healthcare environment and cost-containment initiatives between provinces increase the complexity of operating in the Canadian generics market
    • Key drivers and resistors impacting the Canadian Generics Market
    • A range of resistors impact generic market growth
      • Market exclusivity extension: generics companies must wait longer for generic entry
      • Pseudo-generics: inhibiting ' real' generic growth
    • A number of drivers are helping to drive generics market growth in Canada
      • Compulsory licensing for export to developing countries: theoretically an opportunity for generic growth, but in practice proving complex
      • High cost of generic drugs in Canada relative to rest of world favors generic manufacturers
      • Early working exception policy accelerating speed to market for generic drugs in Canada
      • Biosimilars - a potential new industry
• CHAPTER 3 KEY GENERICS COMPANIES OPERATING IN THE CANADIAN MARKET
  • Introduction
  • Apotex - the largest Canadian-owned generics manufacturer in Canada
    • Overview
    • Company strategy
      • Speed to market
      • Patent challenges
      • Diversification into biosimilars
      • Access to niche markets via Cangene
      • Diversification into proprietary drugs
      • Apotex' s domestic position
    • Company outlook
  • Teva
    • Overview
    • Company strategy
      • First to file patent challenges
      • Good distribution infrastructure in Canada
      • Proprietary drug development
      • Expansion into biosimilar market
    • Company outlook
  • Merck KGaA (Merck Serono)
    • Overview
    • Company strategy
      • Growing pipeline
      • Diversification into more specialist areas
      • Geographic growth by M&A
    • Company outlook
  • ratiopharm
    • Overview
    • Company strategy
      • Geographical expansion
      • Expansion into controlled release delivery market
      • Expansion into biosimilar market
  • Pharmascience - the second largest Canadian-owned generics manufacturer
    • Overview
    • Company strategy
      • Pipeline expansion
      • Manufacturing facilities
      • International ventures
      • Diversification into OTC business
    • Company outlook
  • Other generic pharmaceutical companies
    • Cobalt Pharma
    • Stiefel Laboratories
    • Axcan Pharma
    • Mayne Pharma
    • Ranbaxy
    • Taro Pharmaceuticals
    • Sandoz (Novartis)
• CHAPTER 4 BIBLIOGRAPHY
  • List of Tables
    • Table 1: Estimates of Canadian market size, 2003 and 2005
    • Table 2: Comparison of drug sales per capita
  • List of Figures
    • Figure 1: Ethical sales in Canada 2003-05: $5 billion increase in prescription sales
    • Figure 2: Total market sales and generic sector sales 2002-05
    • Figure 3: The generic market share as a percentage of total pharmaceutical sales varies across markets
    • Figure 4: Key issues in Canadian generic industry, 2007
    • Figure 5: Purpose of launching pseudo-generics/licensed generics globally